Pharmacies Attack $68B Pfizer-Wyeth Deal In 9th Circ.

Law360, San Francisco (May 10, 2011, 7:07 PM EDT) -- A group of pharmacies urged the Ninth Circuit on Tuesday to reinstate its challenge to Pfizer Inc.’s $68 billion merger with Wyeth, arguing the deal has resulted in higher prices and the loss of innovation.

The pharmacies in the long-running case claim the deal — which was completed in 2009 — ran afoul of Section 7 of the Clayton Act and Section 1 of the Sherman Act because Pfizer and Wyeth directly competed with each other in various submarkets of the overall pharmaceutical market.

Joseph Alioto...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.